Standout Papers

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II recepto... 2010 2026 2015 2020 437
  1. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study (2010)
    Luís M. Ruilope, Andrej Dukát et al. The Lancet

Immediate Impact

136 standout
Sub-graph 1 of 20

Citing Papers

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
2024 Standout
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
2024 Standout
16 intermediate papers

Works of Andrej Dukát being referenced

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction
2016
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Andrej Dukát 164 728 282 56 1.0k
Giulia Dell’Omo 186 708 203 47 1.3k
Paula T. Einhorn 158 888 311 37 1.2k
Carlos Campo 133 614 209 74 1.1k
Eigil Fossum 161 859 244 51 1.1k
J NEUTEL 138 796 323 61 985
Yuan‐Yuan Kang 233 916 386 47 1.4k
Juan Carlos Yugar‐Toledo 119 608 248 69 958
Wille Oigman 162 832 336 63 1.3k
Vijaya M Musini 196 681 244 46 1.4k
LE Ramsay 275 569 280 53 1.2k

All Works

Loading papers...

Rankless by CCL
2026